The Synapse Centre for Neurodevelopment ESNEFT (East Suffolk and North Essex NHS Foundation Trust) is a new research centre based in the East of England looking to translate biomedical research into practical therapies for local children and their families with conditions such as Autism, ADHD, Cerebral Palsy, Intellectual disability and Genetic syndromes. It will harness the collective skills of a range of professionals including clinicians, SLTs, physiotherapists and clinical psychologists, backed up by a research department with over 50 years combined experience to deliver research in the NHS. Whilst celebrating neurodiversity amongst its paediatric population, The Synapse Centre seeks to be at the forefront of new era of research seeking to investigate the effects of microbiome / gut-brain axis, immune-metabolism and functional genomics that can impact on brain development. The centre will target innovative new strategies of database acquisition and phenotyping through biomarkers and biometric data. The Synapse Centre for Neurodevelopment ESNEFT will be a collaboration between children, their families, schools, local academic institutions, biotech and pharmaceutical industry to find more personalised approaches to individual diagnoses. It aims to invigorate and transform research in this area to better understand and ameliorate the complex behavioural, developmental and medical comorbidities seen in many children with neurodisabilities.

STALICLA is a mission-driven biotech company, with a unique patient centric vision, that is poised to become a disruptive industry challenger and future global leader in personalized treatment options for patients with Autism Spectrum Disorder (ASD). STALICLA has developed a disruptive approach, the Databased Endophenotyping Patient Identification technology. Databased Endophenotyping Patient Identification uses big data analytics, to match the right treatment with the right ASD patients.

Tertiary Neonates and General Paediatrics